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Depression in later life is usually a recurrent illness
and often a chronic one, associated with increased
health care utilization, amplification of the disabil-
ity born of concurrent medical illness, decreased
quality of life, increased risk for suicide, and cogni-
tive impairment. The good news, however, is that
maintenance treatments work and have a demon-
strably positive impact on long-term illness course.
Treatment response is especially variable, or brittle,
in patients aged over 70; yet maintenance treat-
ment with combined medication and psychother-
apy is able to significantly reduce long-term treat-
ment response variability, ensuring continued
wellness. Further evaluation of cost-effectiveness
is necessary in order to improve reimbursement for
effective long-term treatment.
etting well is not enough;it is staying well
that counts. This theme has guided our research and
clinical practice over the past decade, in completing
the first long-term controlled studies of maintenance
pharmacotherapy and psychotherapy ever conducted
in geriatric depression.
1 Recent data from the World
Health Organization (WHO),
2 clearly illustrate the
importance of taking a long-term view of the clinical
management of depression in later life (and, indeed,
across the life cycle).According to the WHO,unipolar
major depression and suicide accounted for 5.1% of
the global burden of disease in 1990, as measured in
disability-adjusted life years. Of relevance to inter-
vention research in geriatric depression, the signifi-
cance of illness burden attributable to depression
increases with age weighting and thus will grow fur-
ther by the year 2020 based upon projected demo-
graphic shifts towards an older population. Hence,
finding ways of preventing the return of depression
in elderly patients and of maintaining the gains of
acute and continuation treatment would represent a
significant treatment advance and contribution to
public health.
Data from naturalistic studies (not controlling for
treatment or treatment intensity) have identified sev-
eral correlates of relapse and recurrence in geriatric
depression. Correlates, or predictors, of a relapsing
course include a history of frequent prior episodes,
dysthymia, a first onset of major depression after the
age of 60, supervening medical illness, high pretreat-
ment severity of depression and anxiety, incomplete
recovery,and cognitive impairment,especially frontal
lobe dysfunction as signaled by difficulties in initiation
or perseveration.
3-10  Our own studies have suggested
that patients aged 70 and older show more variable,or
brittle,long-term treatment response,probably reflect-
ing the complex biological and psychosocial substrates
of geriatric depression.
11 It is also patients over age
70 who represent a rapidly increasing segment of the
elderly population, whose response to antidepressant
treatment may be the least predictable, and in whom
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Gdepression will increasingly represent a source of
excess medical service utilization and economic cost,
and reduced quality of life, morbidity, and mortality
during the next 20 years.
2,12
Despite the evidence that high treatment intensity
is effective in preventing relapse and recurrence,
9
the intensity of antidepressant treatment prescribed
by psychiatrists begins to decline within 16 weeks of
entry and approximately 10 weeks prior to full
recovery.
4 Residual symptoms of anxiety and exces-
sive worrying predict early recurrence after taper-
ing continuation treatment in elderly depressed
patients.
10 Naturalistic studies, while important for
understanding the illness course of geriatric depres-
sion, leave unanswered questions of importance to
patients, caregivers, clinicians, and health policy ana-
lysts: Can long-term antidepressant treatment
(whether pharmacological, psychosocial, or a com-
bination of both) affect the course of depression in
the elderly, especially those over age 70 in whom
treatment response is more variable and unpre-
dictable? If so, what types of treatment are effective
in which patients, ie, how can clinicians better match
patients and treatment to serve the long-term bene-
fit of the patient? We have addressed these ques-
tions in the research described below.
The first Pittsburgh study of maintenance 
therapies in late-life depression (MTLD-1)
Goal and hypotheses of the MTLD-1 study
In order to address the need for controlled data on
the long-term clinical management of geriatric
depression, we undertook in 1989, with the support
of the National Institute of Mental Health, the first
long-term studies of maintenance pharmacotherapy
and psychotherapy ever conducted in recurrent
major depressive illness of later life. We tested the
hypothesis that maintenance pharmacotherapy with
nortriptyline (NT) and monthly maintenance inter-
personal psychotherapy (IPT), either singly or in
combination, are superior to placebo in preventing
or delaying recurrence of major depressive episodes
in the elderly; and that combined treatment with
both antidepressant medication and interpersonal
psychotherapy is superior to either alone in main-
taining recovery and preventing return of depres-
sive illness.
Summary of methods
The MTLD-1 study recruited 187 elderly patients aged
60 and over with recurrent,nonpsychotic,nondysthymic,
unipolar major depression.Two thirds of the study group
were aged 60 to 69, and one third were 70 and older.
Three quarters of the sample were women and 93%
were white. On average, patients were in their fourth
lifetime episode of major depression at study entry and
had moderate-to-severe depressive symptoms. About
15% had a history of suicide attempts, and about 16%
required inpatient treatment during their index episode.
Most patients had 5 to 6 chronic medical problems, in
addition to depression, for which they were receiving
treatment. This sample had no-to-minimal cognitive
impairment, as measured by the Folstein Mini-Mental
State.
13 About half of the study group were recruited
through clinical referral, and half in response to media
announcements and presentations to lay groups in the
community.
After providing written informed consent, patients
received open combination treatment with NT and
weekly IPT.
14 We titrated NT doses to achieve steady-
state levels of 80 to 120 ng/mL.The goal of acute-phase
combined treatment was to achieve remission of depres-
sive symptoms. The median time to remission was 12
weeks,but speed of response was highly variable.
15
Following successful acute treatment, patients began a
16-week period of continuation therapy, to ensure sta-
bility of remission and to ensure full recovery.Continua-
tion treatment consisted of combined NT and IPT,using
the same dose of NT (an average of 85 mg/day,but with
a range of 20 to 200 mg/day) as during acute therapy,but
reducing the frequency of IPT to twice monthly.
Patients with stable remission and recovery entered
the experimental maintenance phase of the study, via
double-blind random assignment to one of four long-
term treatment conditions: (i) medication clinic with
NT; (ii) medication clinic with placebo; (iii) monthly
maintenance IPT with NT; and (iv) monthly mainte-
nance IPT with placebo. Patients remained in main-
tenance therapy for 3 years, or until recurrence of
major depression, whichever occurred first. Survival
analysis tested differences in rates of recurrence and
time to recurrence.
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at each phase of treatment: 
acute, continuation, and maintenance
Acute treatment
Of 187 patients who signed informed consent to par-
ticipate,5 showed spontaneous remission and 2 declined
to begin treatment. Thus, 180 patients actually began
acute treatment with NT and IPT,and of these 159 com-
pleted acute-phase treatment (140 remitters and 19
nonresponders). Twenty-one patients dropped out of
acute-phase treatment, 8 refusing further treatment, 6
developing medical conditions contraindicating NT, 2
being noncompliant, and 1 each dying or becoming
delusional or manic.
The median time to remission in this sample was 12
weeks,
16 and the earliest point of statistically reliable dis-
crimination of recovering and nonrecovering patients
was 4 weeks.
17 Almost one third (30.5%) showed rapid
sustained response to combined treatment with NT and
IPT,ie,they were well by 4 weeks.Other patients remit-
ted more slowly, by 8 to 10 weeks (22.1%), while the
remaining patients showed partial or mixed response.
Slower and more variable treatment response was asso-
ciated with higher pretreatment levels of anxiety,lower
levels of social support, greater current age at study
entry, and higher percentage of rapid eye movement
(REM) sleep before the initiation of treatment.
15 Sub-
jects with earlier-onset depressive illness (ie,first episode
prior to age 60) took on average 5 to 6 weeks longer to
achieve remission, possibly a reflection of the greater
number of prior lifetime episodes (chronicity).
18 Because
early-onset subjects also had a higher rate of past suicide
attempts,we concluded that they need especially careful
surveillance during acute treatment,since they are likely
to take longer to respond.
Continuation treatment
Of the 140 remitters who entered continuation treat-
ment,124 met study criteria for recovery at the end of 16
weeks of continuation treatment.Nine patients relapsed
and could not be restabilized. Seven subjects dropped
out of treatment,either noncompliant or refusing further
treatment altogether.Thus,124 patients were randomly
assigned to a long-term maintenance therapy condition.
During the 6-week period of double-blind transition to
maintenance therapy, when NT was gradually tapered
and placebo substituted, 13 subjects suffered relapse.A
total of 107 fully recovered patients actually began main-
tenance treatment. Overall, we observed that the rate
of treatment resistance to combined treatment with NT
and IPT, as determined by failure to remit or by subse-
quent relapse during continuation treatment and fail-
ure to recover,was 18%.
19
Maintenance treatment
The primary outcome measure of the MTLD-1 study
was recurrence of major depressive episodes,versus con-
tinued wellness. Both NT (steady-state levels of 80 to
120 ng/mL) and monthly maintenance IPT worked bet-
ter than placebo/medication clinic in preventing recur-
rences of major depression. The best 3-year outcome
was observed with combined NT and IPT.
1 Of patients
randomly assigned to combined treatment, only 20%
suffered recurrence during the 3 years of maintenance
treatment, whereas 90% of those on placebo suffered
recurrence of their depression. Recurrence rates were
intermediate for those in monotherapy: 43% for main-
tenance NT and 64% for monthly maintenance IPT with
placebo.
Higher age at study entry was associated with a greater
liability to recurrence, manifest by higher recurrence
rates generally in those 70 and older.A similar percent-
age of subjects aged 70 and above (40/67, or 59.7%)
entered maintenance treatment,as among subjects aged
60 to 69 (70/113,or 61.9%).Nonetheless,despite identi-
cal recovery rates during acute and continuation therapy
with combined treatment, the overall recurrence rate
during the first year of maintenance treatment was
60.5% (23/40) in subjects aged 70 and older, versus
30.4% (21/69) in those aged 60 to 69.
11 
The steady-state blood level targeted and achieved in
the MTLD-1 study was 80 to 120 ng/mL, with daily
doses ranging from 20 to 200 mg.Doses and blood lev-
els established in the initial acute phase of therapy were
continued into maintenance therapy. In order to test
further whether the effective prophylactic dose is the
same as the acute-phase dose, we conducted a second
parallel study comparing two fixed, steady-state levels
of NT: 80 to 120 ng/mL versus 40 to 60 ng/mL. Recur-
rence rates did not in fact differ significantly in the two
maintenance conditions:40% recurrence over 3 years in
the 80 to 120 ng/mL condition versus 29% recurrence in
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symptoms and minor depressive episodes were more
frequent among patients in the 40 to 60 ng/mL condi-
tion, however, while complaints of constipation were
more frequent and persistent in the 80 to 120 ng/mL
condition.
20 Full-dose maintenance treatment with NT
appears to be preferable to lower-dose maintenance
because of fewer residual symptoms and less variability
of treatment response,as long as the side-effect burden
can be managed effectively.
In addition to addressing our primary question (ie,
does maintenance treatment make a difference in
long-term illness course?), we also addressed the issue
of matching patient with treatment.We reported that
monthly maintenance IPT, without medication, was
effective in preventing recurrence in patients who
reported normal subjective sleep quality by early con-
tinuation treatment.
21 We also observed that long-term
response to maintenance IPT alone was correctly pre-
dicted in 80% of cases by the level of pretreatment
depressive symptoms. Patients with lesser severity of
depression, as manifested by pretreatment Hamilton
depression scores of under 20, generally did well with
maintenance IPT alone, whereas those with more
severe depressions, as manifested by score of 20 or
greater, did better on NT.
22
Conclusion
The good news is that long-term antidepressant treat-
ment can indeed affect the course of depressive illness
positively in later life,helping to maintain wellness and
engagement in life. Combined treatment using both
antidepressant medication and monthly interpersonal
psychotherapy was associated with the highest 3-year
continued-recovery rates (80% in all patients and 67%
in those aged 70 and above).The success of combined
treatment in the elderly attests to the interplay of bio-
logical and psychosocial factors in the onset and offset
of geriatric depression.The greater medical burden of
elderly patients,the frequency of bereavement and role-
transition issues, and the tendency of impaired sleep
quality to persist even into remission,all suggest why a
combined treatment approach may be helpful in dealing
with the liability to recurrence posed by the frail health
and depletion of psychosocial resources characteristic of
the elderly with depression.
Where does the field need to go from here? In the
decade since we undertook the MTLD-1 study, newer
antidepressant medications,the selective serotonin reup-
take inhibitors (SSRIs), have become available, which
are better tolerated by the elderly,safer in the context of
concurrent medical illnesses than tricyclics, and much
less likely to be fatal in overdose.Thus,testing the main-
tenance efficacy of SSRIs,especially in patients aged 70
and above, has the potential of substantial generaliz-
ability.However,due to the lack of controlled data from
geriatric maintenance trials evaluating SSRIs,clinicians
must extrapolate from studies of midlife patients.
23,24
Because combined treatment with medication and IPT
may be the optimal clinical strategy for prevention of
recurrence, we believe that controlled evaluation of
SSRI antidepressant pharmacotherapy combined with
interpersonal psychotherapy should now be undertaken
in over-70 subjects.
Even if the science bears good news about our ability to
positively affect the long-term illness course of geriatric
depression through the use of combined therapy, the
bad news is that current reimbursement for mental
health care in later life falls far short of the mark.There
have been no studies of the cost-effectiveness (that is,
ratio of dollar costs of a treatment to quality adjusted
life years gained by the treatment) for depression inter-
ventions in the elderly.Given the science of our field,the
issue, we believe, is not whether a given treatment is
more cost-effective than no treatment, but specifically
whether combined medication and psychotherapy is
more cost-effective than medication monotherapy.
Clearly this issue has public health policy implications as
well as implications for clinicians as they decide which
treatment is most appropriate for their elderly patients.
The Pittsburgh MTLD-2 study aims to achieve the
objective set forth here of evaluating the long-term effi-
cacy of SSRI therapy, with and without IPT, together
with an assessment of the relative cost-effectiveness of
combined treatment versus medication alone.❏
Supported by grants from the National Institute of Mental Health P30
MH52247, R37 MH43832, R01 MH37869, and K05 MH00295
Clinical research
98REFERENCES
1. Reynolds, CF, Frank E, Perel JM, Nortriptyline and interpersonal psy-
chotherapy as maintenance therapies for recurrent major depression: a ran-
domized controlled trial in patients older than 59 years. JAMA. 1999;28:39-45.
2. World Health Organization. Global Health Statistics: a compendium of
incidence, prevalence and mortality estimates for over 200 conditions. In: The
Global Burden of Disease. Cambridge, Mass: Harvard University Press; 1996. 
3. Zis AP, Grof P, Webster M. Predictors of relapse in recurrent affective
disorders. Psychopharmacol Bull. 19801;6:47-49.
4. Alexopoulos GS, Meyers BS, Young RC, et al. Recovery in geriatric depres-
sion. Arch Gen Psychiatry. 1996;53:305-312.
5. Cole MG, Bellavance F. The prognosis of depression in old age. Am J Geri-
atr Psychiatry. 1997;5:4-14.
6. Baldwin RC, Jolley DJ. The prognosis of depression in old age. Br J Psychi-
atry. 1986;149:574-583.
7. Burvill PW, Hall WD, Stampfer HG. The prognosis of depression in old age.
Br J Psychiatry. 1991;158:64-71.
8. Keller MB, Lavori PW, Collins CE, Klerman GL. Predictors of relapse in
major depressive disorder. JAMA. 1983;250:3299-3304.
9. Georgotas A, McCue RE. Relapse of depressed patients after effective
continuation therapy. J Affect Disord. 1989;17:159-164.
10. Meyers BS, Gabriele MS, Kakuma T, Ippolito L, Alexopoulos G. Anxiety
and recurrence as predictors of recurrence in geriatric depression: a pre-
liminary report. Am J Geriatr Psychiatry. 1996;4:252-257.
11. Reynolds CF, Frank E, Dew MA, et al. Treatment of 70+ year olds with
recurrent major depression. Excellent short-term but brittle long-term
response. Am J Geriatr Psychiatry. 1999;7:64-69. 
12. Unutzer J, Patrick DL, Simon G. Depressive symptoms and the cost of
health services in HMO patients aged 65 years and older. A 4-year prospec-
tive study. JAMA. 1997;277:1618-1623.
13. Folstein MF, Folstein SW, McHugh PR. Mini-Mental State: a practical
method for grading the cognitive state of patients for the clinician. J Psy-
chiatr Res. 1975;12:189-198.
14. Klerman GL, Weissman MM, Rounsaville BJ, Chevron E. Interpersonal Psy-
chotherapy of Depression. New York, NY: Academic Press, Basic Books Inc; 1984.
15. Dew MA, Reynolds CF, Houck PR, et al. Temporal profiles of the course
of depression during treatment: predictors of pathways toward recovery in
the elderly. Arch Gen Psychiatry. 1997;54:1016-1024.
16. Reynolds CF, Frank E, Perel JM, et al. Treatment of consecutive episodes
of major depression in the elderly. Am J Psychiatry. 1994;151:1740-1743.
17. Reynolds CF, Frank E, Dew MA, et al. Discrimination of recovery in the
treatment of elderly patients with recurrent major depression: limits of
prediction. Depression. 1995;2:218-222.
18. Reynolds CF, Dew MA, Frank E, et al. Effects of age at onset of first
lifetime episode of recurrent major depression on treatment response and
illness course in elderly patients. Am J Psychiatry. 1998;155:795-799.
19. Little JT, Reynolds CF, Dew MA, et al. How common is resistance to
treatment in recurrent, nonpsychotic geriatric depression? Am J Psychiatry.
1998;155:1035-1038.
20. Reynolds CF, Perel JM, Frank E, et al. Three-year outcomes of mainte-
nance nortriptyline in late-life depression: a study of two fixed, plasma
levels. Am J Psychiatry. 1999;156:1177-1181.
21. Reynolds CF, Frank E, Houck, PR, et al. Which elderly patients with
remitted depression remain well with continued interpersonal psychother-
apy after discontinuation of antidepressant medication? Am J Psychiatry.
1997;154: 958-962.
22. Taylor MP, Reynolds CF, Frank E. Which elderly depressed patients remain
well on maintenance interpersonal psychotherapy alone? A report from the
Pittsburgh study of maintenance therapies in late-life. Depress Anxiety. In press. 
23. Montgomery SA, Dunbar G. Paroxetine is better than placebo in relapse
prevention and the prophylaxis of recurrent depression. Int Clin Psy-
chopharmacol. 1993;8:189-195.
24. Montgomery SA, Rasmussen JGC, Tanghoj P. A 24-week study of 20 mg
citalopram, 40 mg citalopram, and placebo in the prevention of relapse of
major depression. Int Clin Psychopharmacol. 1993;8:181-188.
Long-term course and outcome of depression in later life - Reynolds Dialogues in Clinical Neuroscience - Vol 1 . No.2 . 1999
Evolucion a largo plazo y consecuencias
de la depresion de aparicion tardia
La depresión en los estadios avanzados de la vida es gen-
eralmente una enfermedad recurrente y a menudo cróni-
ca,que se acompa_a de una utilización creciente de aten-
ción médica,de una amplificación de las incapacidades
causadas por enfermedades somáticas concurrentes,de un
menoscabo de la calidad de vida,de un aumento desl ries-
go de suicidio y de deterioro cognoscitivo.Sin embargo,
hay novedades alentadoras que señalan que los tratamien-
tos de mantención resultan eficaces y poseen un impacto
positivo demostrable sobre la evolución a largo plazo de
la enfermedad.La respuesta al tratamiento es especial-
mente variable o inconsistente en pacientes de más de 70
años;por consiguiente,asociar en el tratamiento de man-
tención medicación y psicoterapia puede reducir significa-
tivamente la variabilidad de la respuesta al tratamiento en
el largo plazo y garantizar beneficios continuos.Es nece-
saria una evaluación adicional respecto a la relación costo-
efecto con el fin de mejorar la adherencia a un tratamien-
to duradero eficaz.
La dépression du sujet âgé : évolution
et pronostic à long terme 
La dépression du sujet âgé est habituellement une mal-
adie récidivante, mais aussi volontiers chronique. Elle
s’associe à un recours accru au système de santé, à une
amplification du handicap du fait de pathologies asso-
ciées,à une baisse de la qualité de vie,à une augmenta-
tion du risque suicidaire et à des perturbations des fonc-
tions cognitives. En contrepartie, il faut souligner l’effi-
cacité du traitement d’entretien qui exerce même un
impact positif démontré sur l’évolution de la maladie à
long terme. La réponse au traitement est particulière-
ment variable, ou fragile, notamment chez les sujets
âgés de plus de 70 ans. Cependant, le traitement d’en-
tretien, dès lors qu’il associe les médicaments et la psy-
chothérapie,est capable de réduire significativement les
fluctuations de la réponse thérapeutique à long terme et
d’assurer la continuité du bien-être. Des études coût-
efficacité complémentaires sont néanmoins nécessaires
pour améliorer le remboursement des traitements qui
font la preuve de leur efficacité au long cours.
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